SV2005002013A - Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo ref. am101382 - Google Patents

Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo ref. am101382

Info

Publication number
SV2005002013A
SV2005002013A SV2005002013A SV2005002013A SV2005002013A SV 2005002013 A SV2005002013 A SV 2005002013A SV 2005002013 A SV2005002013 A SV 2005002013A SV 2005002013 A SV2005002013 A SV 2005002013A SV 2005002013 A SV2005002013 A SV 2005002013A
Authority
SV
El Salvador
Prior art keywords
quinolincarbonitrile
methods
structure ref
protein
inhibitors
Prior art date
Application number
SV2005002013A
Other languages
English (en)
Inventor
Dan Maarten Berger
Dennis William Powell
Bigi Wu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2005002013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2005002013A publication Critical patent/SV2005002013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION PROVEE UN COMPUESTO DE FORMULA 1 (VER FORMULA) EN LA CUAL AR, X, R1, R2, R3 Y R4 SE DEFINEN EN LA PRESENTE, O UNA SAL ACEPTABLE PARA USO FARMACEUTICO DEL MISMO, UTIL EN LA PREVENCION O INHIBICION DE ENFERMEDADES ASOCIADAS CON LA CASCADA DE SEÑALIZACION RAS/RAF/MEK EN UN MAMIFERO, TALES COMO NEOPLASMAS, ACCIDENTES CEREBRO VASCULARES, OSTEOPOROSIS, CANCER, ARTRITIS REUMATOIDEA, ENFERMEDADES INFLAMATORIAS, ENFERMEDAD POLIQUISTICA RENAL Y POLIPOS EN EL COLON Y METODOS DE PREPARACION DE LOS COMPUESTOS DE FORMULA 1 E INTERMEDIARIOS
SV2005002013A 2004-02-20 2005-02-18 Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo ref. am101382 SV2005002013A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54651104P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
SV2005002013A true SV2005002013A (es) 2005-12-06

Family

ID=34910783

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002013A SV2005002013A (es) 2004-02-20 2005-02-18 Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo ref. am101382

Country Status (8)

Country Link
US (2) US7449460B2 (es)
AR (1) AR047709A1 (es)
GT (1) GT200500030A (es)
PA (1) PA8624201A1 (es)
PE (1) PE20051171A1 (es)
SV (1) SV2005002013A (es)
TW (1) TW200529846A (es)
WO (1) WO2005082891A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
MX2011013667A (es) 2009-06-25 2012-03-06 Amgen Inc Compuestos heterociclicos y sus usos.
CA2765823A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Tricyclic heterocyclic compounds as mediators of p13k activity
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
WO2012003264A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2971640C (en) * 2015-07-06 2020-09-22 Gilead Sciences, Inc. Cot modulators and methods of use thereof
WO2017135901A1 (en) * 2016-02-05 2017-08-10 Agency For Science, Technology And Research Heterocyclic compounds, methods of synthesis and uses thereof
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018106184A1 (en) * 2016-12-05 2018-06-14 Agency For Science, Technology And Research Application of multi-kinase inhibitor
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
KR20220161438A (ko) 2020-03-30 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
WO2021202688A1 (en) 2020-04-02 2021-10-07 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
AU3281600A (en) 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
NZ517120A (en) 1999-08-12 2004-10-29 Wyeth Corp NSAID and EFGR kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
AU4545201A (en) 2000-03-13 2001-09-24 American Cyanamid Co Method of treating or inhibiting colonic polyps
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
AU2002210714A1 (en) * 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
CA2357110A1 (en) 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles

Also Published As

Publication number Publication date
US20090062281A1 (en) 2009-03-05
GT200500030A (es) 2005-10-24
WO2005082891A1 (en) 2005-09-09
TW200529846A (en) 2005-09-16
AR047709A1 (es) 2006-02-08
PE20051171A1 (es) 2006-02-02
US7767671B2 (en) 2010-08-03
US20050187247A1 (en) 2005-08-25
PA8624201A1 (es) 2006-06-02
US7449460B2 (en) 2008-11-11

Similar Documents

Publication Publication Date Title
SV2005002013A (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo ref. am101382
CY1121021T1 (el) Ιμιδαζοτριαζινες και ιμιδαζοπυριμιδινες ως αναστολεις κινασης
PE20150729A1 (es) 2,3-benzodiazepines
CU24526B1 (es) Compuestos inhibidores de los receptores endosomales tipo peaje
CR8929A (es) Polimorfo ii de rapamicina y usos del mismo
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CL2008003698A1 (es) Compuestos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina, inhibidores de la btk; composicion farmaceutica que los comprende; y uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune tal como la artritis reumatoide.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
EA201290237A1 (ru) Киназные ингибиторы
CL2008002140A1 (es) Compuestos derivados de azaindol, inhibidores jak; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos proliferativos, cardiacos, neurodegenerativo, asociados con trasplante de organos, artritis reumatoidea, entre otras.
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
TW200745045A (en) Imidazole based LXR modulators
CL2007001920A1 (es) Uso de compuestos derivados de piperidinas sustituidas para inhibir la proteina hdm2 en un mamifero que necesita de esta inhibicion, para el tratamiento o prevencion de enfermedades tales como carcinoma de colon e higado, y leucemia.
AR048912A1 (es) Inmunoglobulinas anti-nogo
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
ECSP099490A (es) Métodos de fabricación y uso de compuestos y composiciones
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
CR20150426A (es) 2,3-benzodiazepinas biciclo y espirocíclico sustituidas
AR057239A1 (es) Inmunoglobulinas
CL2020002275A1 (es) Compuestos diólicos de aminopirazina como inhibidores de pi3k-y.
CY1117828T1 (el) Συνθεσεις για τη θεραπεια νευρολογικων διαταραχων

Legal Events

Date Code Title Description
FD Lapse